Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

The global tinea pedis treatment market is on track for substantial growth, with projections indicating a rise from USD 1,496.3 million in 2024 to USD 2,484 million by 2034. This growth represents a ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

NORTHAMPTON, MA / ACCESSWIRE / October 7, 2024 / Viatris Across all Viatris locations, we are committed to protecting ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

"It could be big. I think it could be as big as some of the others we've gotten here," Anapol Weiss shareholder Kila Baldwin ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Duckhorn (NAPA) to be acquired by Butterfly Equity in $1.95B all-cash deal, with shares jumping over 100% premarket.